Abstract: A method for producing a stamp with a pattern includes deciding a design, the design including three sections separated by three imaginary lines that intersect with one another at a common imaginary point, the design being distributed in the three sections and exhibiting a three-dimensional visual effect; and processing an end of a stamp to form a pattern according to the design, with the pattern exhibiting a three-dimensional visual effect. The stamp includes a body with an end face. The end face includes a pattern having three sections separated by three imaginary lines that intersect with one another at a common imaginary point. The pattern exhibits a three-dimensional visual effect.

Abstract: A magnetic recording medium having a substrate, a granular magnetic layer and a magnetic cap layer covered with carbon overcoat, in this order, wherein both the granular magnetic and magnetic cap layers contain magnetic grains and non-magnetic grain boundaries, and further wherein the magnetic cap layer has denser grain boundaries and the magnetic cap layer contains substantially no oxide is disclosed. The magnetic cap layer serves as both magnetic layer and corrosion barrier for lower HMS.

Abstract: A magnetic recording medium having a substrate, a first magnetic layer having a perpendicular anisotropy and a second magnetic layer having a perpendicular anisotropy, wherein the second magnetic layer contains substantially no dielectric material, (such as, but not limited to, oxides, carbides, and nitrides) is disclosed. Also disclosed is a method for manufacturing the magnetic recording medium of the embodiments of this invention.

Abstract: A method of inhibiting HIV replication in and cellular proliferation of HIV-infected cells. The infected cells are exposed to a single-chain ribosome inactivating protein, at a protein concentration and for an exposure period sufficient to produce a substantial reduction in (a) the level of HIV antigen or reverse transcriptase associated with the infected cells, (b) the ratio of viability of infected/uninfected T cells, and/or (c) the ratio of HIV antigen/cellular antigen in infected macrophages. The method is used to treat HIV infection in humans.